NCT06839443 Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy
| NCT ID | NCT06839443 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro Hospitalar de Lisboa Central |
| Condition | Hidroxicloroquine Intake |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2025-04-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-08-01 with a primary completion date of 2025-04-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hydroxychloroquine retinal toxicity affects a significant number of patients using this medication. Detection of toxicity is difficult in the early stages of the disease and depends on the subjectivity of the clinician who reads the tests (optical coherence tomography, autofluorescence and visual fields). Automating the reading of these diagnostic exams could lead to earlier detection of this pathology and reduce the burden associated with interpreting these exams in the ophthalmology service. The images that are usually taken in the screening and monitoring of hydroxychloroquine toxicity by will be collected - photography of the ocular fundus and optical coherence tomography with autofluorescence.
Eligibility Criteria
Inclusion Criteria: * Patients with \> 10 years of HCQ intake Exclusion Criteria: * Patients with ocular diseases that might mimic HCQ maculopathy or interfer with HCQ maculopathy screening
Contact & Investigator
Rita Anjos, MD
STUDY CHAIR
ULS São José
Frequently Asked Questions
Who can join the NCT06839443 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Hidroxicloroquine Intake. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06839443 currently recruiting?
Yes, NCT06839443 is actively recruiting participants. Contact the research team at RITA.Anjos@gmail.com for enrollment information.
Where is the NCT06839443 trial being conducted?
This trial is being conducted at Portugal, Portugal.
Who is sponsoring the NCT06839443 clinical trial?
NCT06839443 is sponsored by Centro Hospitalar de Lisboa Central. The principal investigator is Rita Anjos, MD at ULS São José. The trial plans to enroll 100 participants.